Digital Content 
NEWS #PharmaBuzz
10 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250609083793/en/Chinas-Center-for-Drug-Evaluation-Accepts-Mercks-Application-for-Marketing-Authorization-of-Pimicotinib-for-Treatment-of-Tenosynovial-Giant-Cell-Tumor
10 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/abbisko-therapeutics-announces-china-nmpa-acceptance-of-new-drug-application-for-pimicotinib-for-the-treatment-of-tgct-302477057.html
29 May 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/pimicotinib-demonstrates-best-in-class-potential-with-significant-efficacy-and-clinically-meaningful-improvements-in-patients-with-tenosynovial-giant-cell-tumor-17217
28 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250527352808/en/Pimicotinib-Demonstrates-Best-in-Class-Potential-with-Significant-Efficacy-and-Clinically-Meaningful-Improvements-in-Patients-with-Tenosynovial-Giant-Cell-Tumor
31 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/merck-exercised-the-option-for-the-global-rights-of-abbisko-therapeuticss-pimicotinib-302416328.html
08 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/2024-ash-oral-presentationabbisko-presents-promising-preliminary-phase-2-study-results-of-pimicotinib-in-the-treatment-of-chronic-graft-versus-host-disease-cgvhd-at-the-66th-ash-annual-meeting-302325684.html
Share 